Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05520385
Other study ID # colorectal CA
Secondary ID
Status Completed
Phase
First received
Last updated
Start date January 1, 2016
Est. completion date February 1, 2019

Study information

Verified date September 2022
Source Al-Kindy Teaching Hospital
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Aim of study: is there possibility of relationship between ABO blood group, Rh & obesity with CRC, that is what we tried to show in this study .


Description:

Cancer is an important leading cause of great psychosocial and economic burden worldwide and about 1.23 million individual annually affected by CRC which is considered as the most common type of cancer ( 9.7 % of overall cancers )and 8 % ( 608,000 case ) died with CRC overall cancer death cases , so it's the fourth most common cause of death among different types of cancer . There is variability in distribution of cases worldwide , as explained by epidemiological data which showed about 60 % of CRC cases presented in developed countries ( 2 % per year ) while in developing countries there is annual increase in the incidence of CRC cases with proportion occurring among patients with age ≤ 40 years is 2 - 8 percent in western countries while in middle east region its about 15 - 35 percent and the incidence rate is less in female than in male with favorable female gender as a prognostic factor over male . There are three different risk groups for CRC, these are FAP, hereditary nonpolyposis colon cancer syndrome (lynch syndrome), and genetic mutations that lead to sporadic colon cancer . The exact cause is unclear but many factors are involved including environmental and genetic . About 24 % of the cases with CRC are due to genetic factors while 75 % of the cases are sporadic and 1 % in patients with pre -existing IBD . Those who immigrates to area with high incidence of CRC from low incidence area may prone to develop CRC which may be related to consumption of red meat and decrease physical activity . The environmental factors including dietary factors like : Lack of fiber , high-fat diet and exposure of mucosa to high levels of bile acids due to impairment of enterohepatic circulation which leading to form carcinogens from degradation of bile salts while previous cholecystectomy has not been proved to be risk for developing CRC . Regarding genetic factors, there are several genes among them Tumor suppressor genes (e.g. APC, p53 ) , Oncogenes (e.g Ras) and Mismatch-repair genes (e.g hMSH2 and hMLH1) were identified as contributing to hereditary colorectal cancer . Here in this study two factors will be discussed with their relation to development of CRC , those factors are ABO blood group , Rh factor and the other one is obesity and as following : Actually , the first human genetic marker are antigens of the ABO system despite of they are a chemical component on erythrocyte membrane but showing expression on variety of epithelial cells including the mucosa of gastrointestinal tract, that was the leading cause observation studies on any correlation between ABO blood group , Rh with tumor . From first studies, Aird et al in 1953 who reported a correlation between ABO Rh factor and carcinoma of stomach , also recently a significant association with pancreatic tumor had been reported . In addition to many studies showed a relationship between ABO antigen expression and CRC . Regarding the obesity , about billion of people are now suffering from obesity worldwide which is considered as one of the strongest factors affecting many health conditions among them some cancers & the prevalence of obesity is rising in many Asian countries including Japan but still lower than western countries . Many epidemiological studies identified high body mass index as independent risk factor for CRC , some of these studies in western countries showing a significant association between BMI and risk of CRC .


Recruitment information / eligibility

Status Completed
Enrollment 102
Est. completion date February 1, 2019
Est. primary completion date January 1, 2019
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 30 Years to 79 Years
Eligibility Inclusion Criteria: - patient with bleeding per rectum - chronic pain in the right iliac fossa with anemia - change in bowel habit - constipation - tinesmus . Exclusion Criteria: - Patient with history of other cancer - those with chronic diseases like H.T, DM , - patients presenting with intestinal obstruction due to tumor - athletics were excluded from the study

Study Design


Related Conditions & MeSH terms


Intervention

Diagnostic Test:
blood group and Rh
check of blood group , Rh for patient and control

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Al-Kindy Teaching Hospital

Outcome

Type Measure Description Time frame Safety issue
Primary an association between occurrence of CRC and blood group A+ , O + . Haemagglutination method was used to detect blood group and Rh factor for patients and control group baseline
Secondary an association between occurrence of CRC and overweight and class ? obesity patients Colonoscopy was done by using Olympus colonoscope , lucera CLV-260 and histopathological examination was done to confirm the diagnosis of CRC basline
See also
  Status Clinical Trial Phase
Recruiting NCT05400122 - Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer Phase 1
Active, not recruiting NCT05551052 - CRC Detection Reliable Assessment With Blood
Completed NCT00098787 - Bevacizumab and Oxaliplatin Combined With Irinotecan or Leucovorin and Fluorouracil in Treating Patients With Metastatic or Recurrent Colorectal Cancer Phase 2
Recruiting NCT06037954 - A Study of Mental Health Care in People With Cancer N/A
Recruiting NCT05425940 - Study of XL092 + Atezolizumab vs Regorafenib in Subjects With Metastatic Colorectal Cancer Phase 3
Suspended NCT04595604 - Long Term Effect of Trimodal Prehabilitation Compared to ERAS in Colorectal Cancer Surgery. N/A
Completed NCT03414125 - Effect of Mailed Invites of Choice of Colonoscopy or FIT vs. Mailed FIT Alone on Colorectal Cancer Screening N/A
Completed NCT02963831 - A Study to Investigate ONCOS-102 in Combination With Durvalumab in Subjects With Advanced Peritoneal Malignancies Phase 1/Phase 2
Recruiting NCT05489211 - Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03) Phase 2
Terminated NCT01847599 - Educational Intervention to Adherence of Patients Treated by Capecitabine +/- Lapatinib N/A
Completed NCT05799976 - Text Message-Based Nudges Prior to Primary Care Visits to Increase Care Gap Closure N/A
Recruiting NCT03874026 - Study of Folfiri/Cetuximab in FcGammaRIIIa V/V Stage IV Colorectal Cancer Patients Phase 2
Active, not recruiting NCT03170960 - Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors Phase 1/Phase 2
Completed NCT03167125 - Participatory Research to Advance Colon Cancer Prevention N/A
Completed NCT03181334 - The C-SPAN Coalition: Colorectal Cancer Screening and Patient Navigation N/A
Recruiting NCT04258137 - Circulating DNA to Improve Outcome of Oncology PatiEnt. A Randomized Study N/A
Recruiting NCT05568420 - A Study of the Possible Effects of Medication on Young Onset Colorectal Cancer (YOCRC)
Recruiting NCT02972541 - Neoadjuvant Chemotherapy Verse Surgery Alone After Stent Placement for Obstructive Colonic Cancer N/A
Completed NCT02876224 - Study of Cobimetinib in Combination With Atezolizumab and Bevacizumab in Participants With Gastrointestinal and Other Tumors Phase 1
Completed NCT01943500 - Collection of Blood Specimens for Circulating Tumor Cell Analysis N/A